Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label, Single Arm Safety Prospective Cohort Study of Dabigatran Etexilate for Secondary Prevention of Venous Thromboembolism in Children From 0 to Less Than 18 Years

NCT02197416 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT02197416
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02197416 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label, Single Arm Safety Prospective Cohort Study of Dabigatran Etexilate for Secondary Prevention of Venous Thromboembolism in Children From 0 to Less Than 18 Years
Lead sponsor
Boehringer Ingelheim
Phase
Phase 3
Overall status
Completed
Start date
September 29, 2014
Completion date
November 19, 2019
Enrollment
214 (actual)
Sites
62

Conditions

As the registry lists them; a condition with its own page is linked.

secondary prevention, venous thromboembolism